322 related articles for article (PubMed ID: 17973542)
1. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
[TBL] [Abstract][Full Text] [Related]
2. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
3. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL
Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460
[TBL] [Abstract][Full Text] [Related]
4. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
[TBL] [Abstract][Full Text] [Related]
5. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
6. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Pariente A; Sanctussy DJ; Miremont-Salamé G; Moore N; Haramburu F; Fourrier-Réglat A;
CNS Drugs; 2010 Jan; 24(1):55-63. PubMed ID: 20030419
[TBL] [Abstract][Full Text] [Related]
10. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
[TBL] [Abstract][Full Text] [Related]
11. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Goh CW; Aw CC; Lee JH; Chen CP; Browne ER
Drug Metab Dispos; 2011 Mar; 39(3):402-11. PubMed ID: 21148081
[TBL] [Abstract][Full Text] [Related]
13. Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database.
Magro L; Arzenton E; Leone R; Stano MG; Vezzaro M; Rudolph A; Castagna I; Moretti U
Front Pharmacol; 2020; 11():622862. PubMed ID: 33536925
[No Abstract] [Full Text] [Related]
14. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Farlow MR
Clin Ther; 2001; 23 Suppl A():A13-24. PubMed ID: 11396867
[TBL] [Abstract][Full Text] [Related]
16. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
17. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
Auffret M; Labreuche J; Duhamel A; Deheul S; Cottencin O; Bordet R; Gautier S; Rolland B
Drug Saf; 2017 Mar; 40(3):257-262. PubMed ID: 27988884
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug-Drug Interactions: An Analysis From the French Pharmacovigilance Database.
Létinier L; Ferreira A; Marceron A; Babin M; Micallef J; Miremont-Salamé G; Pariente A;
Front Pharmacol; 2020; 11():624562. PubMed ID: 33841134
[TBL] [Abstract][Full Text] [Related]
19. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
